• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ras, PI3K and mTORC2 - three's a crowd?Ras、PI3K 和 mTORC2——三足鼎立?
J Cell Sci. 2020 Oct 8;133(19):jcs234930. doi: 10.1242/jcs.234930.
2
Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.mTORC1和mTORC2的离散信号传导机制:在细胞和分子层面既相互联系又彼此独立。
Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4.
3
Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.缺氧抑制人乳头瘤病毒癌基因表达是通过 PI3K/mTORC2/AKT 信号通路介导的。
mBio. 2019 Feb 12;10(1):e02323-18. doi: 10.1128/mBio.02323-18.
4
Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate.磷脂酰肌醇 3,4,5-三磷酸直接激活 mTORC2 激酶活性的证据。
J Biol Chem. 2011 Apr 1;286(13):10998-1002. doi: 10.1074/jbc.M110.195016. Epub 2011 Feb 10.
5
Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.mTOR复合物的多种信号传导机制:mTORC1和mTORC2形成紧密关系。
Adv Biol Regul. 2019 May;72:51-62. doi: 10.1016/j.jbior.2019.03.003. Epub 2019 Apr 11.
6
Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.生长因子通过 Class 1 和 Class 3 PI3Ks 激活 SGK3 的机制。
Biochem J. 2018 Jan 2;475(1):117-135. doi: 10.1042/BCJ20170650.
7
Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.解析 mTOR 复合物(mTORC1 和 mTORC2)的信号通路,作为胶质母细胞瘤的治疗靶点。
Adv Biol Regul. 2022 Jan;83:100854. doi: 10.1016/j.jbior.2021.100854. Epub 2021 Dec 6.
8
PI3K/Akt promotes feedforward mTORC2 activation through IKKα.磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/Akt)通过IKKα促进前馈性哺乳动物雷帕霉素靶蛋白复合物2(mTORC2)激活。
Oncotarget. 2016 Apr 19;7(16):21064-75. doi: 10.18632/oncotarget.8383.
9
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.Ran 是一种潜在的治疗靶点,适用于那些具有与 PI3K/Akt/mTORC1 和 Ras/MEK/ERK 通路激活相关的分子变化的癌细胞。
Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.
10
-Diarylurea Derivatives (CTPPU) Inhibited NSCLC Cell Growth and Induced Cell Cycle Arrest through Akt/GSK-3β/c-Myc Signaling Pathway.二芳基脲衍生物(CTPPU)通过 Akt/GSK-3β/c-Myc 信号通路抑制非小细胞肺癌细胞生长并诱导细胞周期停滞。
Int J Mol Sci. 2023 Jan 10;24(2):1357. doi: 10.3390/ijms24021357.

引用本文的文献

1
Polyploid cancer cells reveal signatures of chemotherapy resistance.多倍体癌细胞揭示了化疗耐药的特征。
Oncogene. 2025 Mar;44(7):439-449. doi: 10.1038/s41388-024-03212-z. Epub 2024 Nov 22.
2
Polyploid cancer cells reveal signatures of chemotherapy resistance.多倍体癌细胞揭示了化疗耐药的特征。
Res Sq. 2024 Oct 14:rs.3.rs-4921634. doi: 10.21203/rs.3.rs-4921634/v1.
3
Polyploid cancer cells reveal signatures of chemotherapy resistance.多倍体癌细胞揭示了化疗耐药的特征。
bioRxiv. 2024 Aug 23:2024.08.19.608632. doi: 10.1101/2024.08.19.608632.
4
A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS.一种新型的 MTORC2-AKT-ROS 轴在药物诱导的突变 KRAS 激活后触发结直肠癌细胞的线粒体裂变和线粒体自噬相关执行。
Autophagy. 2024 Jun;20(6):1418-1441. doi: 10.1080/15548627.2024.2307224. Epub 2024 Feb 25.
5
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.联合使用酪氨酸激酶抑制剂卡博替尼和 mTORC1/2 抑制剂 Sapanisertib 阻断 ERK 通路活性并抑制肾细胞癌肿瘤生长。
Cancer Res. 2023 Dec 15;83(24):4161-4178. doi: 10.1158/0008-5472.CAN-23-0604.
6
CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.CRISPR 介导的致癌 KRAS 突变的逆转导致增殖增加,并揭示 Ras 和 mTORC2 在 A549 肺癌细胞迁移中的独立作用。
Mol Biol Cell. 2023 Dec 1;34(13):ar128. doi: 10.1091/mbc.E23-05-0152. Epub 2023 Sep 20.
7
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.靶向小分子 GTP 酶:KRAS 开创的针对先前无法控制的靶点的新兴方法。
Signal Transduct Target Ther. 2023 May 23;8(1):212. doi: 10.1038/s41392-023-01441-4.
8
Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy.雷帕霉素在癫痫中 mTOR 信号通路及其抑制剂的研究进展。
Brain Behav. 2023 Jun;13(6):e2995. doi: 10.1002/brb3.2995. Epub 2023 May 23.
9
Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion.Ras 介导的 mTORC2 激活促进乳腺上皮细胞迁移和侵袭。
Mol Biol Cell. 2023 Feb 1;34(2):ar9. doi: 10.1091/mbc.E22-06-0236. Epub 2022 Dec 21.
10
Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism.在肾癌细胞中,锯齿状蛋白-1(Jagged-1)通过一种Akt/ALK5/ Smad4依赖性机制被mTOR抑制剂诱导产生。
Curr Res Pharmacol Drug Discov. 2022 Jul 4;3:100117. doi: 10.1016/j.crphar.2022.100117. eCollection 2022.

本文引用的文献

1
mTOR at the nexus of nutrition, growth, ageing and disease.mTOR 在营养、生长、衰老和疾病的交汇点。
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203. doi: 10.1038/s41580-019-0199-y. Epub 2020 Jan 14.
2
Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling.活性 Ras 与 mSIN1 的直接物理相互作用调节 mTORC2 信号通路。
BMC Cancer. 2019 Dec 19;19(1):1236. doi: 10.1186/s12885-019-6422-6.
3
Integrated actions of mTOR complexes 1 and 2 for growth and development of Dictyostelium.雷帕霉素靶蛋白复合物1和2对盘基网柄菌生长发育的综合作用
Int J Dev Biol. 2019;63(8-9-10):521-527. doi: 10.1387/ijdb.190245ak.
4
Does Ras Activate Raf and PI3K Allosterically?Ras是否通过变构作用激活Raf和PI3K?
Front Oncol. 2019 Nov 15;9:1231. doi: 10.3389/fonc.2019.01231. eCollection 2019.
5
Growth Factor-Dependent and -Independent Activation of mTORC2.生长因子依赖和不依赖的 mTORC2 激活。
Trends Endocrinol Metab. 2020 Jan;31(1):13-24. doi: 10.1016/j.tem.2019.09.005. Epub 2019 Nov 4.
6
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.致癌信号与癌症代谢交界处的 PI3K-AKT 网络。
Nat Rev Cancer. 2020 Feb;20(2):74-88. doi: 10.1038/s41568-019-0216-7. Epub 2019 Nov 4.
7
A Comparative Analysis of Individual RAS Mutations in Cancer Biology.癌症生物学中个体RAS突变的比较分析
Front Oncol. 2019 Oct 18;9:1088. doi: 10.3389/fonc.2019.01088. eCollection 2019.
8
Therapeutic targeting of RAS: New hope for drugging the "undruggable".靶向治疗 RAS:为“不可成药”带来新希望。
Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118570. doi: 10.1016/j.bbamcr.2019.118570. Epub 2019 Oct 31.
9
Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.I 类磷酸肌醇 3-激酶(PI3K)调节亚基及其在信号转导和疾病中的作用。
Adv Biol Regul. 2020 Jan;75:100657. doi: 10.1016/j.jbior.2019.100657. Epub 2019 Sep 28.
10
Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance.mTORC1 和 mTORC2 在乳腺癌中的作用:靶向 mTOR 及其伙伴克服转移和耐药性的治疗。
Adv Exp Med Biol. 2019;1152:283-292. doi: 10.1007/978-3-030-20301-6_15.

Ras、PI3K 和 mTORC2——三足鼎立?

Ras, PI3K and mTORC2 - three's a crowd?

机构信息

Department of Molecular & Cellular Biology, Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, USA.

Department of Molecular & Cellular Biology, Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, USA

出版信息

J Cell Sci. 2020 Oct 8;133(19):jcs234930. doi: 10.1242/jcs.234930.

DOI:10.1242/jcs.234930
PMID:33033115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7561475/
Abstract

The Ras oncogene is notoriously difficult to target with specific therapeutics. Consequently, there is interest to better understand the Ras signaling pathways to identify potential targetable effectors. Recently, the mechanistic target of rapamycin complex 2 (mTORC2) was identified as an evolutionarily conserved Ras effector. mTORC2 regulates essential cellular processes, including metabolism, survival, growth, proliferation and migration. Moreover, increasing evidence implicate mTORC2 in oncogenesis. Little is known about the regulation of mTORC2 activity, but proposed mechanisms include a role for phosphatidylinositol (3,4,5)-trisphosphate - which is produced by class I phosphatidylinositol 3-kinases (PI3Ks), well-characterized Ras effectors. Therefore, the relationship between Ras, PI3K and mTORC2, in both normal physiology and cancer is unclear; moreover, seemingly conflicting observations have been reported. Here, we review the evidence on potential links between Ras, PI3K and mTORC2. Interestingly, data suggest that Ras and PI3K are both direct regulators of mTORC2 but that they act on distinct pools of mTORC2: Ras activates mTORC2 at the plasma membrane, whereas PI3K activates mTORC2 at intracellular compartments. Consequently, we propose a model to explain how Ras and PI3K can differentially regulate mTORC2, and highlight the diversity in the mechanisms of mTORC2 regulation, which appear to be determined by the stimulus, cell type, and the molecularly and spatially distinct mTORC2 pools.

摘要

Ras 癌基因是众所周知的难以用特定的治疗方法来靶向。因此,人们有兴趣更好地了解 Ras 信号通路,以确定潜在的可靶向效应物。最近,雷帕霉素复合物 2 (mTORC2) 的机械靶点被确定为一种进化上保守的 Ras 效应物。mTORC2 调节包括代谢、存活、生长、增殖和迁移在内的基本细胞过程。此外,越来越多的证据表明 mTORC2 与肿瘤发生有关。关于 mTORC2 活性的调节知之甚少,但提出的机制包括磷脂酰肌醇 (3,4,5)-三磷酸 (PI3K) 的作用,PI3K 是一种特征明确的 Ras 效应物。因此,Ras、PI3K 和 mTORC2 在正常生理和癌症中的关系尚不清楚;此外,还报道了一些看似相互矛盾的观察结果。在这里,我们回顾了 Ras、PI3K 和 mTORC2 之间潜在联系的证据。有趣的是,数据表明 Ras 和 PI3K 都是 mTORC2 的直接调节因子,但它们作用于 mTORC2 的不同池:Ras 在质膜上激活 mTORC2,而 PI3K 在细胞内隔室中激活 mTORC2。因此,我们提出了一个模型来解释 Ras 和 PI3K 如何能够差异调节 mTORC2,并强调了 mTORC2 调节机制的多样性,这似乎取决于刺激、细胞类型以及分子和空间上不同的 mTORC2 池。